TY - JOUR T1 - Genome-wide Analysis of Copy Number Variation in Latin American Parkinson’s Disease Patients JF - medRxiv DO - 10.1101/2020.05.29.20100859 SP - 2020.05.29.20100859 AU - Elif Irem Sarihan AU - Eduardo Pérez-Palma AU - Lisa-Marie Niestroj AU - Douglas Loesch AU - Miguel Inca-Martinez AU - Andrea R. V. R. Horimoto AU - Mario Cornejo-Olivas AU - Luis Torres AU - Pilar Mazzetti AU - Carlos Cosentino AU - Elison Sarapura-Castro AU - Andrea Rivera-Valdivia AU - Elena Dieguez AU - Victor Raggio AU - Andres Lescano AU - Vitor Tumas AU - Vanderci Borges AU - Henrique B. Ferraz AU - Carlos R. Rieder AU - Artur Schumacher-Schuh AU - Bruno L. Santos-Lobato AU - Carlos Velez-Pardo AU - Marlene Jimenez-Del-Rio AU - Francisco Lopera AU - Sonia Moreno AU - Pedro Chana-Cuevas AU - William Fernandez AU - Gonzalo Arboleda AU - Humberto Arboleda AU - Carlos E. Arboleda-Bustos AU - Dora Yearout AU - Cyrus P. Zabetian AU - Timothy A. Thornton AU - Timothy D. O’Connor AU - Dennis Lal AU - Ignacio F. Mata AU - on behalf of the Latin American Research Consortium on the Genetics of Parkinson’s Disease (LARGE-PD) Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.05.29.20100859.abstract N2 - Background Parkinson’s disease is the second most common neurodegenerative disorder and affects people from all ethnic backgrounds, yet little is known about the genetics of Parkinson’s disease in non-European populations. In addition, the overall identification of copy number variants at a genome-wide level has been understudied in Parkinson’s disease patients.Objectives To understand the genome-wide burden of copy number variants in Latinos and its association with Parkinson’s disease.Methods We used genome-wide genotyping data from 747 Parkinson’s disease patients and 632 ancestry matched controls from the Latin American Research Consortium on the Genetics of Parkinson’s disease.Results Genome-wide copy number burden analysis showed no difference between patients vs. controls, whereas patients were significantly enriched for copy number variants overlapping known Parkinson’s disease genes compared to controls (Odds Ratio: 3.97 [1.69 - 10.5], P = 0.018). PARK2 showed the strongest copy number burden, with 20 copy number variant carriers. These patients presented an earlier age of disease onset compared to patients with other copy number variants (median age at onset: 31 years vs. 57 years, P = 7.46 x 10-7).Conclusions We found that Parkinson’s disease patients are significantly enriched with copy number variants affecting known Parkinson’s disease genes. We also identified that out of 250 patients with early-onset disease, 5.6% carried a copy number variant on PARK2 in our cohort. Our study is the first to analyze genome-wide copy number variants association in Latino Parkinson’s disease patients and provides insights about this complex disease in this understudied population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a Stanley Fahn Junior Faculty Award from the Parkinson's Foundation and supported by a research grant from the American Parkinson's Disease Association, with resources and the use of facilities at the Veterans Affairs Puget Sound Health Care System.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by VA Puget Sound IRB, with the project name "LARGE-PD: Latin American Research Consortium of the Genetics of Parkinson's Disease", RDIS number: 0010, MIRB number: 00087. Currently, the study is under Cleveland Clinic IRB: 19-340.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and methods are reported in the article and in the Supplement. https://github.com/elifirem/LargePD_CNV ER -